Kornimate/medical-research-clean huggingface dataset:
telehealth implementation of brain-computer interface

Conditions: Amyotrophic Lateral Sclerosis; Stroke

Summary: determine if telehealth intervention can allow/empower a caregiver (who is untrained) to effectively implement and utilize a brain-computer interface for communication with a participant who is "locked in" following progression of amyotrophic lateral sclerosis and other conditions.

people with amyotrophic lateral sclerosis (als) or other conditions such as a pontine stroke may develop a condition called locked in syndrome (lis) where they are unable to use alternative communication strategies such as eyegaze to allow for communication for social needs or instruction to caregivers. brain-computer interface (bci) devices have been shown in the laboratory to allow participants to effectively communicate needs and engage in social communication. however, translation of this research to the home environment has been limited. in order to be a functional option for people to utilize, bci needs to be much easier to set up and operate. this study is designed to determine if telehealth intervention is sufficient to allow an untrained caregiver to set up and maintain a bci for a person with a long-term communication difficulty given lis. participants will receive a computer and associated hardware to allow for set up of the bci. videoconference support will be provided by the research team to allow the client and caregiver to set up the device in their home. participants will hopefully be able to use the device to generate novel communication related to their care and engage in social needs with caregivers and/or family members. communication that is generated will be logged and times that the participant is engaged in use of the bci when not under direct support by the researchers will also be monitored. the hypothesis is that telehealth support will be sufficient to allow for setting up the computer. if this is true, this will make it much easier for a client to engage in use of a bci to allow for that communication versus the current need of traveling to a clinic or other specialized setting.

Eligibility criteria:
inclusion criteria: * diagnosis leading to severe communication impairment exclusion criteria: -

Keywords: locked in syndrome
study on left atrial function of atrial fibrillation after radiofrequency ablation with statin therapy

Conditions: Atrial Fibrillation

Summary: a total of 120 patients with persistent atrial fibrillation (including continuous and long-standing persistent atrial fibrillation) and 60 patients with paroxysmal atrial fibrillation will receive radiofrequency ablation. patients in each group will be randomly allocated into the statin treatment group and non-statin treatment group (allocation ratio, 1:1). left atrial appendage flow velocity of all patients are measured by transesophageal echocardiography(tee) 24 hours before the operation. real-time ultrasound examinations of left atrial function are carried out for all patients before the operation and after the operation. blood samples are extracted in all patients before the operation and after the operation. this study will clarify whether the application of statin drugs can improve postoperative left atrial function. this study will identify the time course and influence factors of left atrial recovery of atrial fibrillation after the operation to guide the time and the degree of anticoagulation and effectively prevent thromboembolic events. at the same time, biochemical indicators are detected to analyze which indicators are related to the postoperative recurrence of atrial fibrillation, the incidence of postoperative thrombosis and the recovery of postoperative left atrial function. furthermore, this study will investigate whether the application of statin drugs can improve postoperative left atrial function by affecting these indicators.


Eligibility criteria:
inclusion criteria: * all persistent or permanent af patients with refractory or intolerant to at least one class 1 or class 3 antiarrhythmic medication. * paroxysmal atrial fibrillation with refractory or intolerant to at least one class 1 or class 3 antiarrhythmic medication. * age is \<80 years exclusion criteria: * left ventricular dysfunction * la \>50 mm * atrial thrombosis * valvular heart disease * hyperthyroidism * patients who underwent prosthetic heart valve replacement * patients with previous history of atrial fibrillation ablation * hyperlipidemia * pregnant women * patients with existing liver and kidney disease * malignant tumors * hematological system diseases

Keywords: atrial fibrillation;left atrial function
an observational study on long-term persistence of resistant mutations and durability of sustained virological response in patients with chronic hepatitis c treated with direct acting antiviral (daa)- containing regimens

Conditions: Hepatitis C, Chronic

Summary: this observational long-term follow-up study will assess the persistence of direct acting antiviral (daa) resistant mutations and the durability of sustained virological response in patients with chronic hepatitis c who have participated in a roche daa treatment protocol. up to 5 scheduled monitoring visits for blood sampling during an observational period of up to 36 months.


Eligibility criteria:
inclusion criteria: * adult patients, \>/=18 years of age * chronic hepatitis c * participation in roche daa treatment protocol for chc infection * daa-associated resistant mutations persisting through to last evaluation in donor protocol , or partial viral response or viral load rebound while on ro5024048 treatment, or sustained virological response \>/= 20 weeks after last dose of study medication in donor study exclusion criteria: * for patients participating in daa resistance monitoring: initiation of treatment after participation in the donor protocol for which there is evidence of cross-resistance to donor protocol daa * for patients participating in daa svr durability: treatment with any anti-hvc therapy since establishing svr in the donor study
stroke volume analysis during aortic valve replacement trial

Conditions: Hemodynamic Monitoring; Cardiac Output; Cardiac Surgery

Summary: compromised peripheral tissue oxygenation during surgery may lead to worse patient outcome, mainly due to post-operative infections or heart failure. insufficient stroke volume and/or cardiac output due to hypovolemia or cardiac defects play a central role in causing poor peripheral tissue oxygenation. in order to assess stroke volume, there are numerous invasive and non-invasive methods available. up to the present date it is unknown, if these methods may by used interchangeably in patients with severe cardiac defects like aortic stenosis.


Eligibility criteria:
inclusion criteria: * scheduled transcatheter aortic valve implantation * signed patient consent form * aged 18 or older by time of surgery * no participation in other clinical trials exclusion criteria: * pregnant or breast-feeding women * emergency surgery

Keywords: hemodynamic monitoring cardiac output cardiac surgery
lactation outcomes among survivors of pediatric cancer

Conditions: Cancer; Leukemia

Summary: while the majority of women in the general population can breastfeed successfully, the investigators have limited knowledge about the correlates and sequelae of lactation success among women treated for pediatric malignancies. childhood cancer treatments are known to cause late effects that frequently involve the endocrine system. because normal lactation is dependent upon interplay of multiple endocrine factors, the investigators anticipate more breastfeeding difficulties in survivors that have diabetes, growth hormone deficiencies, thyroid disorders and obesity. in order to more fully inform clinicians and female survivors, the study of the burden of lactation failure is needed to begin to address the impact of pediatric cancer therapy on lactation success/failure and to examine the association of specific endocrine disorders on lactation outcomes.

participants will complete a cross-sectional survey. responses will be compared with a national sample of healthy women from project first (infant feeding practices survey ii). primary objective: * to describe breastfeeding outcomes (intention, initiation, duration, and weaning) among female sjlife protocol participants 18 years of age and older who reported a live birth. secondary objective: * to compare breastfeeding outcomes between childhood cancer survivors and healthy mothers.

Eligibility criteria:
inclusion criteria: * participants in the sjlife protocol or patients in the after completion of therapy (act) clinic, both at st. jude children's research hospital. * female * 18 years of age or older * at least one reported live birth after childhood cancer diagnosis and treatment. exclusion criteria: * unable to read and write. * unable to read and understand english.

Keywords: lactation pediatric malignancies cancer survivor
treatment of mature b-cell lymphoma/leukaemia

Conditions: B-Cell Lymphoma

Summary: this is an international trial conducted by three cooperative groups: sfop (france, belgium, netherlands), ccg (usa, canada, australia), and ukccsg (uk and ireland). children with mature b-cell lymphoma/leukaemia are stratified into three different risk groups (a, b, c) and receive treatment of progressive intensity. randomized trials in the 2 biggest groups (b and c) test whether "reduced" therapy is equivalent to standard intensive therapy (lmb-89 b and c) in terms of event free survival. the reason for the modification is to reduce the long term toxicity which includes cardiotoxicity, impaired fertility and secondary malignancy. in group b, the modifications of treatment consists of a reduction of cyclophosphamide in copadm2 and/or the elimination of copadm3. in group c, the modification consists in a reduction of the doses in the cyve courses and the elimination of the last 3 courses of maintenance treatment

group b: randomized trial with factorial design. the 4 treatment arms are standard lmb89 therapy b, reduction of cyclophosphamide (cpm) in copadm2, deletion of copadm3, both reduction and deletion. randomization occurs following copadm1 and is stratified for national group, histology (large cell; small non cleaved cell) and stage (murphy i orii; murphy iii+ldh\ 2n or murphy iv). the primary analysis questions are whether reducing cpm dose in copadm2 results in a smaller long-term efs whether omitting copadm3 results in a smaller long-term efs group c: randomized trial. the 2 treatment arms are standard lmb89 therapy c versus reduction of cyve + deletion of the last 3 maintenance courses. randomization occurs following copadm2 and is stratified for national group, histology (large cell; small non cleaved cell) and cns disease. the primary analysis question is whether reducing cyve and omitting the last 3 maintenance courses result in a smaller long-term efs than standard lmb 89 treatment c

Eligibility criteria:
inclusion criteria: * newly diagnosed b lineage non-hodgkin's lymphoma with revised european american lymphoma (real) ii 9 (diffuse large cell lymphoma), 10 (burkitt's lymphoma), or 11 (high grade b cell lymphoma, burkitt's like) or bone marrow \> 5% l3 blasts. * pre treatment imaging studies adequate to document murphy disease stage * group b and c patients are eligible for randomization (therapy stratification by group : group a=completely resected stage i or completely resected abdominal stage ii lesions, group b= all cases not eligible for group a or group c, group c= any cns involvement and/or bone marrow involvement ³ 25% blasts) * patients should be available for a minimum follow up of 36 months * informed consent prior to study entry exclusion criteria: * anaplastic large cell ki 1 positive lymphomas * previous chemotherapy. * congenital immunodeficiency * prior organ transplantation * previous malignancy of any type * known hiv positivity

Keywords: b-cell lymphoma
effect of folic acid and/or pentoxifylline on patients with chronic kidney disease

Conditions: Chronic Kidney Diseases

Summary: the aim of this study is to evaluate the effect of administration of folic acid and /or pentoxifylline on patients with chronic kidney disease (ckd).

chronic kidney disease (ckd) is a worldwide public health problem, with adverse outcomes of kidney failure, cardiovascular disease (cvd), and premature death. chronic kidney disease (ckd) affects between 8% and 16% of the population worldwide.defined by a glomerular filtration rate (gfr) of less than 60 ml/min/1.73 m2, albuminuria of at least 30 mg per 24 hours, or markers of kidney damage (eg, hematuria or structural abnormalities such as polycystic or dysplastic kidneys) persisting for more than 3 months.that nutrient loss because of diet restriction and chronic inflammation contributed by ckd itself may stimulate progression in advanced chronic kidney disease. folic acid was then selected as a nutrient intervention. in the mean time, pentoxifylline was well studied in this field for its anti-inflammatory effects.pentoxifylline (ptf) appears to improve circulation through its ability to alter erythrocyte deformability and enhances capillary microcirculation. this hemorheological property and the potential capacity in decreasing intraglomerular pressure has led to recent interest in ptf as a therapeutic agent in patients with kidney disease. in addition to these properties, ptf has an effect on inflammation, oxidative stress and endothelial function.

Eligibility criteria:
inclusion criteria: 1. patients who have chronic kidney disease(ckd) stages 3-5 2. aged between18 - 60 years old. 3. both sexes. 4. stable clinical condition defined as no hospitalizations or cardiovascular events within the 3 months before screening 5. stable renal function (baseline serum creatinine had to have not increased by 50% in the 3 months before screening) 6. no changes in concomitant medication during the study. 7. patients who accept to participate in the study. exclusion criteria: 1. pregnant women 2. current use of ptf 3. contraindication to use of ptf drug: history of ptf or theophylline allergy, history of severe retinal hemorrhage or recent cerebral hemorrhage 4. those with active infections or inflammatory diseases or hiv infection 5. those with chronic liver disease . 6. patients who had received immunosuppressive therapy 7. non-compliant patients
a study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in participants with previously treated kras g12c-positive advanced or metastatic non-small cell lung cancer

Conditions: Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer

Summary: the purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved kras g12c inhibitors (sotorasib or adagrasib) in participants with kras g12c-positive (kras g12c +) advanced or metastatic non-small cell lung cancer (nsclc).


Eligibility criteria:
inclusion criteria: * unequivocal histologically or cytologically confirmed diagnosis of metastatic or locally advanced nsclc not amenable to treatment with surgical resection or combined chemoradiation * disease progression during or after treatment with at least one prior systemic therapy but no more than three lines of prior systemic therapy in the advanced or metastatic setting * measurable disease according to response evaluation criteria in solid tumors (recist) v1.1 * documentation of the presence of a kras g12c mutation * availability of a representative formalin-fixed, paraffin-embedded (ffpe) tumor specimen in a paraffin block (preferred) or 10-15 (15 preferred) unstained, freshly cut, serial slides with an associated pathology report * eastern cooperative oncology group (ecog) performance status of 0 or 1 * life expectancy of \>= 12 weeks exclusion criteria: * known hypersensitivity to any of the components of divarasib, or sotorasib or adagrasib * malabsorption syndrome or other condition that would interfere with enteral absorption * known concomitant second oncogenic driver * mixed small-cell lung cancer or large cell neuroendocrine histology * known and untreated, or active central nervous system (cns) metastases * leptomeningeal disease or carcinomatous meningitis * uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures biweekly or more frequently * any infection that, in the opinion of the investigator, could impact patient safety, or treatment with therapeutic oral or iv antibiotics within 14 days prior to day 1 of cycle 1 * prior treatment with any kras g12c inhibitor or pan-kras/ras inhibitor * more than 30 gy of radiotherapy to the lung within 6 months of randomization * uncontrolled tumor-related pain * unresolved toxicities from prior anticancer therapy * history of malignancy within 5 years prior to screening, with the exception of the cancer under investigation in this study and malignancies with a negligible risk of metastasis or death (e.g., 5-year os rate \>90%), such as adequately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or stage i uterine cancer

Keywords: advanced non-small cell lung cancer kras g12 lung cancer advanced lung cancer metastatic lung cancer divarasib kras g12c inhibitor kras g12c positive kras mutation kras g12c mutation lung cancer mutation
comparing the effects of mobilization with movement (mwm), self mwm, and dynamic stretching on hip internal rotation)

Conditions: Hip; Anomaly

Summary: this study is looking to address the effectiveness of three different intervention on hip range of motion. there will be a therapist performed mobilization group, a self mobilization group, and a dynamic stretching group. participants will be recruited from the university of south carolina and randomly assigned between the three groups to have equal distribution and limit any biases. participants will come in on two different days in order to receive the intervention on the first and have hip range of motion measured on both days. the investigators will be assessing if there is any significant difference between the three groups.

the goal of this study is to compare the efficacy of three clinical interventions intended to treat hip dysfunctions such as hip osteoarthritis. physical therapists utilize mobilization with movement clinically to increase range of motion that has been limited by hip pathology. this study will compare mobilization with movement administered by a physical therapist, self-administered mobilization with movement, in which patients are instructed in the maneuver and then perform it at home, and dynamic stretching as instructed by a physical therapist. efficacy will be judged through changes in hip internal rotation range of motion, a motion which is typically limited in patients with hip pathology. the objectives of the study are to quantify the effects of two different modalities of hip mobilization with movement and dynamic stretching in terms of hip internal rotation increases, and to inform current physical therapy practice by filling gaps in the literature surrounding the therapeutic effects of hip mobilization with movement. this study is intended to better equip physical therapists to select the most appropriate evidence-based interventions, thereby increasing the quality of patient care.

Eligibility criteria:
inclusion criteria: * \<30 degrees hip internal rotation in at least 1 hip exclusion criteria: * traumatic injury in last 6 months * fai * fracture * surgery within last 6 months * positive faddir/faber * symptomatic oa * ra * neurologic conditions

Keywords: hip mobilization on hip internal rotation
to evaluate the safety and efficacy of inhaled ct-p63 and ct-p66 combination therapy in symptomatic patients with covid-19 not requiring supplemental oxygen

Conditions: COVID-19

Summary: this is a phase 3 study to assess the efficacy about therapeutic effect of inhaled ct-p63 and ct-p66 combination therapy to symptomatic patiemts with covid-19 and overall safety.

ct-p63 and ct-p66 are monoclonal antibodies targeted against sars-cov-2 spike receptor binding domain as a treatment for covid-19 infection. ct-p63 and ct-p66 are currently being developed by the sponsor as a potential treatment for covid-19 infection. in this study, efficacy, safety, and virology of inhaled ct-p63 and ct-p66 will be evaluated in symptomatic patients with covid-19 infection.

Eligibility criteria:
inclusion criteria: * adult male or female patient, aged 18 or above. * patient diagnosed with sars-cov-2 infection at screening by using the sponsor-supplied rapid sars-cov-2 diagnostic test or rt-pcr. * patient with conditions meeting all of the following criteria: 1. oxygen saturation ≥ 94% on room air. 2. not requiring supplemental oxygen. * patient who has onset of one or more of the sars-cov-2 infection associated symptoms within 7 days prior to the study drug administration. exclusion criteria: * patient with current serious condition meeting one of the following: 1. previously or currently hospitalized or requires hospitalization for treatment of serious sars-cov-2 related conditions. 2. respiratory distress with respiratory rate ≥30 breaths/min. 3. severe pneumonia 4. requires supplemental oxygen 5. experience shock 6. complicated with other organs failure, and intensive care unit monitoring treatment is needed by investigator's discretion. * patient who has received or has a plan to receive any of following prohibited medications or treatments: 1. drugs with actual or possible antiviral drugs and/or possible anti-sars-cov-2 activity including but not limited to nirmatrelvir and ritonavir, molnupiravir, remdesivir, chloroquine, hydroxychloroquine, dexamethasone (or alternative corticosteroids to dexamethasone), and other immunomodulatory agents and human immunodeficiency virus protease inhibitors for therapeutic purpose of sars-cov-2 infection prior to study drug administration 2. any sars-cov-2 human intravenous immunoglobulin, convalescent plasma for the treatment of covid-19 infection prior to study drug administration 3. any approved monoclonal antibody (sotrovimab, casirivimab and imdevimab, bamlanivimab and etesevimab, etc), any other investigational device or medical product including but not limited to any monoclonal antibody(tocilizumab, sarilumab, etc.), fusion proteins or biologics for the treatment of covid-19 infection prior to the first study drug administration. 4. any investigational vaccine for sars-cov-2.